TOULOUSE, France--(BUSINESS WIRE)--Regulatory News:
VEXIM (Paris:ALVXM) (FR0011072602 - ALVXM), a medical device company specializing in the minimally invasive treatment of vertebral fractures, announces the nomination of Steve Swinson as new Chairman of the Board of Directors.
“Vexim and the Board of Directors are proud to welcome Steve Swinson as Chairman of the Board of Vexim. Steve is a man of action and a proven leader with a strong expertise in international business and medical devices development. His considerable experience will strengthen our Board and be a real asset at a time when Vexim continues to expand its footprint across the vertebral fracture market and promotes its SpineJack device worldwide,” said Vincent Gardès, CEO of Vexim.
“Vexim has a unique positioning in the medical devices market. Its innovative technology has already proven itself, and I am convinced that the company has all the assets needed to become a global leader in the spine trauma market. I am very pleased to join this venture, and I am eager to contribute to the company’s development,” commented Steve Swinson, Chairman of Vexim.
Prior to joining Vexim's board Steve Swinson was responsible for leading the Spine & Biologics business for Western Europe and Canada at Medtronic. He was previously International Vice President for Spine & Biologics.
Previously at Medtronic, he was Vice President for Emerging Markets responsible for P&L and operating margins for all Medtronic product lines, covering a wide geography from South Asia including India, Africa, Middle East and Latin America.
Steve Swinson has over 30 years’ experience in international business. He managed the indirect channel of distributors for Hewlett Packard Medical Products Group in Europe and was Vice President of Marquette Medical Systems for Asia Pacific. He also managed the Diagnostic X-ray business on global basis for GE Medical Systems in 2002.
Steve Swinson holds a PhD in electrical engineering from Manchester University in the United Kingdom and an MBA from the University of Chicago.
New Vexim Board composition is the following:
- Steve Swinson, Board Member and Chairman of Vexim
- Vincent Gardès, Board Member and CEO of Vexim
- Philippe Pouletty, Board Member and representing Truffle Capital
- Antoine Pau, Board Member
- Marie-Laure Pochon, Board Member
- Douglas Beall, Board Member
- Bernard Belloc, Board Member
- Phillipe Boucheron, Observer and representing BPI
***
About VEXIM, the innovative back microsurgery specialist
Based
in Balma, near Toulouse (France), VEXIM is a medical device company
created in February 2006. The company has specialized in the creation
and marketing of minimally-invasive solutions for treating traumatic
spinal pathologies. Benefitting from the financial support of it
longstanding shareholder, Truffle Capital1 and from BPI
public subsidies, VEXIM has designed and developed the SpineJack®, a
unique implant capable of repairing a fractured vertebra and restoring
the balance of the spinal column. The Company currently has 60 members
on its staff. It has its own sales teams in France, Germany, Italy,
Spain, Switzerland, the United Kingdom and United States, as well as
distributors in Turkey, Argentina, Taiwan, Belgium, Estonia, Poland,
Portugal, South Africa, Saudi Arabia, Colombia, Panama, Venezuela,
Chile, Peru and Ecuador and in the following countries where the product
is currently being registered: Mexico, Brazil. VEXIM has been listed on
NYSE Alternext Paris since May 2012.
For further information,
please visit www.vexim.com
SpineJack®, a revolutionary implant for treating Vertebral Fractures
The
revolutionary aspect of the SpineJack® lies in its ability to restore a
fractured vertebra to its original shape, restore the spinal column’s
optimal anatomy and thus remove pain and enable the patient to recover
their functional capabilities. Thanks to a specialized range of
instruments, inserting the implants into the vertebra is carried out by
minimally-invasive surgery, guided by X-ray, in approximately 30
minutes, enabling the patient to be discharged shortly after surgery.
The SpineJack® range consists of 3 titanium implants with 3 different
diameters, thus covering 95% of vertebral fractures and all patient
morphologies.
SpineJack® technology benefits from the support of
international scientific experts in the field of spinal surgery and
worldwide patent protection through to 2029.
|
1 Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.
